Welcome to Immunsystem AB

Background and milestones

IMMUNSYSTEM was founded in 1983 by Anders Larsson from Uppsala University and Per-Erik Wejåker from the Swedish University of Agriculture. The researchers brought together the disciplines of protein research and animal handling. Much of their work was done in the production and use of antibodies within diagnostics. Over the years, inherent advantages were found with avian antibodies (IgY) and the focus of the company shifted towards using IgY. During the following years, IMMUNSYSTEM developed kits for screening of specific analytes and offered a large selection of purified antibodies for use in diagnostics.

IMMUNSYSTEM was approached by Hans Kollberg, at the time doctor at the Cystic Fibrosis center, Akademiska Hospital in Uppsala. The idea from this meeting was that avian antibodies should be possible to use for the prevention and treatment of microbial infections. In this field of immune therapy, hens are vaccinated with the microbe that is associated with a certain indication. Due to the susceptibility of CF patients to acquire infections with Pseudomonas aeruginosa, the first clinical tests were set up in this area. Promising results indicated a proof-of-concept. The study of CF patients was continued and at the same time clinics were run for infections common in other indications.

GMP production of Anti-Pseudomonas IgY was set up in Sweden. Based on reported results from preclinical and clinical studies in the CF study, the Swedish Medical Products Agency in November 2003 gave special permission to CF patients to be treated with IMMUNSYSTEM's Anti-Pseudomonas IgY. The Swedish government reimburses this treatment.

With a continued focus on immune therapy, a major milestone was achieved in 2008 when the European Medicines Agency (EMEA) granted an orphan drug designation to IMMUNSYSTEM’s drug candidate for treatment of cystic fibrosis.

  IgY molecule